
News|Articles|March 1, 2005
Exenatide: A novel incretin mimetic hormone for the treatment of type 2 diabetes
A number of clinical approaches are utilized in managing the overlapping aspects of poor glycemic control in patients with type 2 diabetes. Exenatide (Amylin/Lilly), a novel drug in a new medication class known as the incretin mimetic agents, offers a new mechanism to achieve glycemic control.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
2
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
3
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
4
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
5



















































